A clinical-stage RNAi therapeutic candidate for IPF mediates durable MMP7 silencing in nonhuman primates and human lung tissue
Year: 2023
Type: conference-abstract
Institution: Arrowhead Pharmaceuticals (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4387981070
